financetom
Business
financetom
/
Business
/
Update: Market Chatter: Large Hess Shareholder to Abstain From Vote on Chevron Takeover
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Market Chatter: Large Hess Shareholder to Abstain From Vote on Chevron Takeover
May 17, 2024 9:37 AM

12:06 PM EDT, 05/17/2024 (MT Newswires) -- (Updates with additional details in the third, fourth, and fifth paragraphs)

Hess (HES) shareholder D.E. Shaw intends to abstain from voting on Chevron's ( CVX ) planned $53 billion takeover of the oil company, Bloomberg reported Friday, citing Managing Director Jason Singer.

D.E. Shaw is one of the top 15 shareholders in Hess, according to the report.

Singer said D.E. Shaw would support Institutional Shareholder Services' motion to delay voting on the deal until there is more clarity around Chevron ( CVX ) and Hess' arbitration case with Exxon Mobil ( XOM ) . Another Hess shareholder HBK Capital Management also supports the motion, the report added.

"The transaction, as currently structured, doesn't contemplate the time it takes to arbitrate with Exxon. As long-term holders, we believe Hess is a high-quality company with attractive assets and a bright future" Singer was quoted as saying.

"We look forward to Hess obtaining a successful shareholder vote and completing the transaction," Chevron ( CVX ) told MT Newswires.

D.E. Shaw and Hess did not immediately respond to MT Newswires' requests for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 156.79, Change: +0.47, Percent Change: +0.30

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Simon Property Group misses quarterly funds from operations estimates
Simon Property Group misses quarterly funds from operations estimates
Nov 4, 2024
(Reuters) - Commercial real estate investment trust Simon Property Group ( SPG ) missed market expectations for third-quarter funds from operations (FFO) on Friday, hurt by softer leasing demand at its mixed-use shopping centers. The company reported FFO, a key measure of performance of a REIT, of $2.84 per share for the quarter ended Sept. 30 down from $3.20 per...
Lexicon Pharmaceuticals Says FDA Panel Opposes Zynquista for Type 1 Diabetes and Kidney Disease
Lexicon Pharmaceuticals Says FDA Panel Opposes Zynquista for Type 1 Diabetes and Kidney Disease
Nov 4, 2024
08:51 AM EDT, 11/01/2024 (MT Newswires) -- Lexicon Pharmaceuticals ( LXRX ) said late Thursday that the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration voted 11-3 against recommending Zynquista (sotagliflozin) as an add-on to insulin therapy for glycemic control in adults suffering from type 1 diabetes and chronic kidney disease. The committee cited concerns...
Sector Update: Consumer
Sector Update: Consumer
Nov 4, 2024
08:49 AM EDT, 11/01/2024 (MT Newswires) -- Consumer stocks were advancing premarket Friday with the Consumer Staples Select Sector SPDR Fund (XLP) 0.4% higher and the Consumer Discretionary Select Sector SPDR Fund (XLY) up 1.9% recently. Wayfair ( W ) shares rose by over 2% after the company reported it swung to an adjusted profit in Q3 while revenue declined...
Femasys Says It Received US Patent for Female Birth Control Device FemBloc
Femasys Says It Received US Patent for Female Birth Control Device FemBloc
Nov 4, 2024
08:53 AM EDT, 11/01/2024 (MT Newswires) -- Femasys ( FEMY ) said Friday that it received a new US patent covering FemBloc, its permanent, non-surgical birth control device for women. The company said the patent, valid until at least 2039, supports Femasys' ( FEMY ) intellectual property protection for FemBloc as it progresses through clinical trials. Femasys ( FEMY )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved